TITLE
Human Papillomavirus Virus-like-participle Protein
CASE NUMBER
C04137
ABSTRACT
Virus-like particles (VLPs) are extraordinary molecules that resemble and mimic the structure of authentic viruses without being infectious. Since they do not contain any viral genetic material, they are able to elicit a strong immune response, without doing any actual harm. JHU researchers have developed a series of human papillomavirus (HPV) VLPs (purified HPV Types 6, 11, 16, and 18 VLPs) for use as research tools.
Related HPV VLP Publications by Dr. Viscidi
Viscidi, R. P., Ahdieh-Grant, L., Clayman, B., Fox, K., Massad, L. S., Cu-Uvin, S., . . . Miotti, P. (2003). Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. Journal of Infectious Diseases, 187(2), 194-205. doi:10.1086/346052
Viscidi, R. P., Ahdieh-Grant, L., Schneider, M. F., Clayman, B., Massad, L. S., Anastos, K. M., . . . Strickler, H. (2003). Serum immunoglobulin A response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HFV)-positive and high-risk HIV-negative women. Journal of Infectious Diseases, 188(12), 1834-1844. doi:10.1086/379975
Viscidi, R. P., & Clayman, B. (2006). Serological cross reactivity between polyomavirus capsids doi:10.1007/0-387-32957-9_5
Viscidi, R. P., Kotloff, K. L., Clayman, B., Russ, K., Shapiro, S., & Shah, K. V. (1997). Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clinical and Diagnostic Laboratory Immunology, 4(2), 122-126. Viscidi, R. P., Rollison, D. E., Sondak, V. K., Silver, B., Messina, J. L., Giuliano, A. R., . . . Rivanera, D. (2011). Age-specific seroprevalence of merkel cell polyomavirus, BK virus, and JC virus. Clinical and Vaccine Immunology, 18(10), 1737-1743. doi:10.1128/CVI.05175-11
Viscidi, R. P., Rollison, D. E. M., Viscidi, E., Clayman, B., Rubalcaba, E., Daniel, R., . . . Shah, K. V. (2003). Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clinical and Diagnostic Laboratory Immunology, 10(2), 278-285. doi:10.1128/CDLI.10.2.278-285.2003
Viscidi, R. P., Schiffman, M., Hildesheim, A., Herrero, R., Castle, P. E., Bratti, M. C., . . . Burk, R. D. (2004). Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: Results from a population-based study in costa rica. Cancer Epidemiology Biomarkers and Prevention, 13(2), 324-327. doi:10.1158/1055-9965.EPI-03-0166
Viscidi, R. P., & Shah, K. V. (2007). Cervarix™. human papillomavirus vaccine. Drugs of the Future, 32(11), 952-956. doi:10.1358/dof.2007.032.11.1150372
Viscidi, R. P., Snyder, B., Cu-Uvin, S., Hogan, J. W., Clayman, B., Klein, R. S., . . . Shah, K. V. (2005). Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiology Biomarkers and Prevention, 14(1), 283-288.
CONTACT INFORMATION
Nakisha Holder
Technology Licensing Associate
Johns Hopkins Technology Ventures
410-516-7787
nickki@jhu.edu
